<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Immunizations in patients with end-stage kidney disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Immunizations in patients with end-stage kidney disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Immunizations in patients with end-stage kidney disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn Whitaker, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 19, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4212047188"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Infections are a leading cause of morbidity and mortality among patients with end-stage kidney disease (ESKD) [<a href="#rid1">1</a>]. Although vaccines can help prevent many of the most common infections to which these patients are exposed, patients with ESKD have a reduced response to vaccination.</p><p>Immunization recommendations in the United States are developed by the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) and are shown in the figures  (<a class="graphic graphic_figure graphicRef82634" href="/z/d/graphic/82634.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef62130" href="/z/d/graphic/62130.html" rel="external">figure 2</a>). This topic will review vaccination strategies and efficacy in patients with ESKD, focusing upon the vaccines of most importance for this population.</p><p>Immunizations in kidney transplant candidates and recipients are presented separately. (See  <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">"Immunizations in solid organ transplant candidates and recipients"</a>.)</p><p class="headingAnchor" id="H2758546300"><span class="h1">APPROACH TO VACCINATION</span></p><p class="headingAnchor" id="H2905174688"><span class="h2">Recommended vaccines</span><span class="headingEndMark"> — </span>Patients with end-stage kidney disease (ESKD) who are not up to date on other routinely recommended vaccines (based on age and other risk factors) should receive any needed vaccines  (<a class="graphic graphic_figure graphicRef82634" href="/z/d/graphic/82634.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef62130" href="/z/d/graphic/62130.html" rel="external">figure 2</a>). If patients with ESKD are traveling, they should undergo evaluation for additional vaccination based on their travel destination and potential exposures. (See  <a class="medical medical_review" href="/z/d/html/2876.html" rel="external">"Standard immunizations for children and adolescents: Overview"</a> and  <a class="medical medical_review" href="/z/d/html/3884.html" rel="external">"Standard immunizations for nonpregnant adults"</a>.)</p><p>In <strong>addition</strong> to routine vaccines recommended for the general population, patients with ESKD should receive the following vaccines: </p><p class="bulletIndent1"><span class="glyph">●</span>Hepatitis B virus (HBV) vaccine (see <a class="local">'Hepatitis B virus vaccine'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Pneumococcal vaccine (see <a class="local">'Pneumococcal vaccine'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory syncytial virus (RSV) vaccine (for individuals ≥60 years of age) (see <a class="local">'Respiratory syncytial virus vaccine'</a> below)</p><p></p><p>This approach to vaccination is generally consistent with the Advisory Committee on Immunization Practices (ACIP) in the United States [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H2902386242"><span class="h2">Timing of vaccination</span><span class="headingEndMark"> — </span>For patients with ESKD who are kidney transplant candidates, any needed vaccines should be administered as early as possible provided that a minimum time interval is maintained between vaccination and subsequent transplantation. This time interval depends on whether the vaccine is inactivated or live (see  <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">"Immunizations in solid organ transplant candidates and recipients", section on 'Timing of immunizations'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>For inactivated vaccines, vaccination should be completed at least two weeks prior to transplant [<a href="#rid3">3</a>]. Although vaccine responses may be diminished in some patients during the pretransplant period, vaccine responses are even more attenuated posttransplantation, when the patient is immunosuppressed.  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For live vaccines (eg, the measles, mumps, and rubella [MMR] vaccine), vaccination should be completed at least four weeks prior to transplant and is generally contraindicated posttransplantation when patients are immunosuppressed [<a href="#rid3">3</a>]. </p><p></p><p>For patients with ESKD who are not transplant candidates, any needed vaccines also should be administered as early as possible.</p><p class="headingAnchor" id="H4197327118"><span class="h1">VACCINE EFFICACY IN END-STAGE KIDNEY DISEASE</span><span class="headingEndMark"> — </span>Patients with end-stage kidney disease (ESKD) have a reduced response to vaccination due to immune dysregulation [<a href="#rid4">4</a>]. Compared with vaccinated patients without ESKD, for example, patients on dialysis have a lower antibody titer and an inability to maintain adequate antibody titers over time [<a href="#rid5">5,6</a>]. The relatively low antibody response to vaccination also appears to correlate with the degree of kidney failure but not with the specific mode of dialysis [<a href="#rid7">7</a>]. It appears that disturbances in T lymphocytes and antigen-presenting cells may be responsible for the altered acquired immunity in this population [<a href="#rid8">8-10</a>].</p><p>Despite the decreased antibody response, vaccination remains an important preventative measure for patients with ESKD. The efficacy of specific vaccines in this patient population is presented below.</p><p class="headingAnchor" id="H3188701328"><span class="h2">Hepatitis B virus vaccine</span><span class="headingEndMark"> — </span>All patients with ESKD should receive hepatitis B virus (HBV) vaccination [<a href="#rid2">2</a>]. The dose, route, and vaccine types are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3641.html" rel="external">"Hepatitis B virus immunization in adults", section on 'Indications'</a> and  <a class="medical medical_review" href="/z/d/html/3641.html" rel="external">"Hepatitis B virus immunization in adults", section on 'Patients on dialysis and immunocompromised hosts'</a>.)</p><p>Cases of HBV infection in hemodialysis units prompted the Centers for Disease Control (CDC) to recommend that all patients with ESKD, on dialysis or predialysis, receive HBV vaccination [<a href="#rid11">11,12</a>]. Support for the recommendation is provided by a case-control study that found that patients on hemodialysis vaccinated against HBV had a 70 percent lower risk for infection compared with nonvaccinated patients [<a href="#rid13">13</a>]. The CDC suggested that the cost of vaccinating patients is mitigated by the reduced need for monthly surveillance of antigen and antibody status in those who develop specific antibodies [<a href="#rid11">11</a>].</p><p>Patients with ESKD have a reduced response to HBV vaccination. Compared with a response rate of &gt;90 percent in patients without kidney failure, only 50 to 60 percent of those with ESKD develop antibodies following HBV vaccination [<a href="#rid14">14,15</a>]. </p><p>Although HIV infection decreases the effectiveness of the HBV vaccine, this risk does not appear to be greater among patients on dialysis [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/z/d/html/15807.html" rel="external">"Prevention of hepatitis B virus infection in adults with HIV", section on 'Vaccination'</a>.)</p><p>Because of the generally low response rate among patients with ESKD, the following strategies have been used to improve antibody production to HBV vaccine in this population: </p><p class="bulletIndent1"><span class="glyph">●</span>Doubling the dose of vaccine (ie, 40 mcg/dose in patients with ESKD) [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/3641.html" rel="external">"Hepatitis B virus immunization in adults", section on 'Patients on dialysis and immunocompromised hosts'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Giving an HBV vaccine that uses a novel immunostimulatory adjuvant [<a href="#rid18">18,19</a>]. (See  <a class="medical medical_review" href="/z/d/html/3641.html" rel="external">"Hepatitis B virus immunization in adults", section on 'Yeast-derived'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beginning the vaccination series as soon as chronic kidney disease (CKD) is recognized and the patient is known to be hepatitis B surface antigen (HBsAg) and antibody negative; the clinician should not wait until the patient is dialysis dependent to begin the vaccination protocol [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administering an additional vaccine series to patients on dialysis who failed to respond to the initial series, which is defined as antibody titers ≤10 international units/L one to two months after completion of the first series [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administering a single booster dose if the antibody titer falls to ≤10 international units/L in the patient who initially developed an antibody response to vaccination or after natural infection [<a href="#rid20">20,21</a>]. There appears to be no benefit to repeated boosters in those whose antibody titers remain ≤10 international units/L. (See  <a class="medical medical_review" href="/z/d/html/3641.html" rel="external">"Hepatitis B virus immunization in adults", section on 'When a booster dose should be administered'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Giving a combined hepatitis A and B vaccine [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/z/d/html/3641.html" rel="external">"Hepatitis B virus immunization in adults", section on 'Combination vaccines'</a>.)</p><p></p><p>Additional investigational approaches are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3641.html" rel="external">"Hepatitis B virus immunization in adults", section on 'New developments'</a>.)</p><p>Clinicians should be aware that HBsAg may be detected up to 18 days following HBV vaccination and up to 52 days in patients on hemodialysis [<a href="#rid23">23,24</a>]. This result is clinically insignificant, and it has been recommended that testing for HBsAg be avoided within three weeks of vaccination [<a href="#rid25">25</a>] and potentially longer in patients on hemodialysis.</p><p>Despite the availability of the HBV vaccine, the most important factor in preventing the spread of HBV in a hemodialysis unit is the maintenance of universal precautions. The CDC also recommends isolating antigen-positive patients and prohibiting the use of shared medications (eg, common heparin vials) among patients on dialysis [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H4269168862"><span class="h2">Pneumococcal vaccine</span><span class="headingEndMark"> — </span>All patients with ESKD should receive pneumococcal vaccination  (<a class="graphic graphic_table graphicRef86782" href="/z/d/graphic/86782.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef143140" href="/z/d/graphic/143140.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef143139" href="/z/d/graphic/143139.html" rel="external">table 3</a>). This approach is consistent with the recommendations of the Advisory Committee on Immunization Practices (ACIP) [<a href="#rid2">2</a>]. The dose, route, and vaccine types and intervals are discussed at length elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults", section on 'Vaccine administration'</a>.)</p><p>Vaccination against pneumococcal disease is associated with decreased mortality among patients with ESKD [<a href="#rid26">26</a>]. Despite these data, and the recommendations of the ACIP, overall pneumococcal vaccination rates among patients ESKD remain suboptimal [<a href="#rid27">27</a>]. </p><p>The antibody response to the pneumococcal vaccine can be variable among patients with CKD and ESKD. As an example, in a study of 155 patients on chronic hemodialysis over 50 years of age who received pneumococcal vaccination, significant immunity was maintained for one year following vaccination [<a href="#rid28">28</a>]. However, in another study of 44 children and young adults with CKD, only approximately one-half of the patients maintained sufficient immunity at one year [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H3579765563"><span class="h2">Influenza vaccine</span><span class="headingEndMark"> — </span>All patients with ESKD should receive an influenza vaccine annually as per the general population [<a href="#rid2">2</a>]. Additional details regarding available vaccine formulations, schedule, and administration are discussed at length elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">"Seasonal influenza vaccination in adults", section on 'Formulations'</a>.)</p><p>The antibody response to the standard-dose influenza vaccine in patients on chronic hemodialysis is lower than that in the general population [<a href="#rid30">30-33</a>]. In addition, a clear advantage of influenza vaccination on the rates of influenza infection, pneumonia, hospitalization, and mortality has not been demonstrated among patients with ESKD [<a href="#rid26">26,34,35</a>]. Despite these data, we continue to vaccinate patients with ESKD against influenza to mitigate the potential morbidity and mortality risk of an influenza infection [<a href="#rid36">36</a>].</p><p>It is uncertain whether the use of a high-dose vaccine may improve influenza vaccine efficacy in patients on dialysis. Observational studies of patients on dialysis have reported that a high-dose influenza vaccine is associated with a more sustained antibody response [<a href="#rid37">37</a>] and a lower hospitalization rate [<a href="#rid38">38</a>] compared with a standard-dose vaccine. However, another study did not observe an association between a high-dose vaccine and lower risk of hospitalization [<a href="#rid39">39</a>], and no study to date of patients on dialysis has reported a mortality benefit of a high-dose compared with a standard-dose influenza vaccine [<a href="#rid38">38,39</a>]. </p><p class="headingAnchor" id="H3793994411"><span class="h2">Varicella-zoster virus vaccine</span><span class="headingEndMark"> — </span>Patients with ESKD who are ≥50 years old should receive the recombinant (non-live) zoster vaccine (RZV). This approach is consistent with recommendations of the ACIP [<a href="#rid2">2</a>]. In patients between 19 and 50 years old who are receiving immunosuppressive therapy, vaccination with RZV may also be indicated. Additional detail regarding types of vaccines and vaccine administration is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8343.html" rel="external">"Vaccination for the prevention of shingles (herpes zoster)"</a>.)</p><p>Among patients on dialysis, a zoster infection is associated with a higher mortality [<a href="#rid40">40</a>], and administration of the live attenuated zoster vaccine is associated with a lower risk of developing zoster when compared with unvaccinated age-, sex-, and dialysis duration-matched controls [<a href="#rid41">41</a>]. However, the preferential use of the recombinant vaccine is based upon its greater efficacy and sustained immunity against zoster in other populations. The recombinant vaccine is well tolerated in patients on hemodialysis [<a href="#rid42">42</a>].</p><p>Additional data regarding the comparative efficacy of the recombinant vaccine versus the live attenuated vaccine are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8343.html" rel="external">"Vaccination for the prevention of shingles (herpes zoster)", section on 'Available vaccines'</a>.)</p><p class="headingAnchor" id="H1297797824"><span class="h2">Tetanus, diphtheria, and pertussis vaccine</span><span class="headingEndMark"> — </span>Patients with ESKD should receive vaccination with the tetanus, diphtheria, and pertussis (Tdap) vaccine as recommended for the general population. (See  <a class="medical medical_review" href="/z/d/html/2838.html" rel="external">"Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age"</a> and  <a class="medical medical_review" href="/z/d/html/2844.html" rel="external">"Diphtheria, tetanus, and pertussis immunization in children 6 weeks through 6 years of age"</a> and  <a class="medical medical_review" href="/z/d/html/3897.html" rel="external">"Tetanus-diphtheria toxoid vaccination in adults"</a> and  <a class="medical medical_review" href="/z/d/html/8044.html" rel="external">"Pertussis infection in adolescents and adults: Treatment and prevention"</a>.)</p><p>Data on the efficacy of the tetanus vaccine in patients with CKD are limited but suggest that the response is less than in patients with normal kidney function. A prospective, controlled study evaluated the response to tetanus and HBV vaccines among 23 patients with nondialysis CKD, 27 patients on dialysis, 7 transplant recipients, and 15 healthy controls [<a href="#rid43">43</a>]. All healthy individuals and six of seven transplant recipients seroconverted after three doses of tetanus toxoid vaccine; by comparison, antibodies developed in only 69 and 55 percent of patients on dialysis and those with CKD, respectively. If present, antibody titers were lower in the groups with kidney function impairment than in those without kidney disease. Patients who had previously responded to HBV vaccine were more likely to respond to tetanus vaccine, implying that a subset of patients has a more intact immune system. Despite the reduced response to tetanus vaccine, most patients on dialysis develop antibodies, thereby making vaccination effective for most patients [<a href="#rid7">7</a>].</p><p>There are no published data describing the vaccine response among patients with ESKD to the diphtheria or pertussis components of the Tdap vaccine.</p><p class="headingAnchor" id="H3486728186"><span class="h2">Human papillomavirus vaccine</span><span class="headingEndMark"> — </span>Vaccination against human papillomavirus (HPV) is appropriate for patients with ESKD who have an indication based upon recommendations for the general population  (<a class="graphic graphic_figure graphicRef82634" href="/z/d/graphic/82634.html" rel="external">figure 1</a>) [<a href="#rid44">44</a>]. This vaccine protects against HPV types that are responsible for most cervical cancers and genital warts and is most effective when administered before the onset of sexual activity. (See  <a class="medical medical_review" href="/z/d/html/8325.html" rel="external">"Human papillomavirus vaccination"</a>.)</p><p>Studies examining the efficacy of the HPV vaccine among patients with CKD have shown that the vaccine appears to be safe and has short-term efficacy [<a href="#rid45">45,46</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>A study of 57 females aged 9 to 21 years with CKD (n = 25), on dialysis (n = 9), or post-kidney transplantation (n = 23) who received the standard three-dose HPV vaccine found 100 percent antibody response at &lt;12 months and ≥12 months in those with CKD and on dialysis [<a href="#rid45">45</a>]. Maintenance of the antibody response was significantly less among transplanted patients, prompting the authors to call for additional study in this population [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study of 65 patients aged 9 to 18 years with CKD, on dialysis, or post-kidney transplantation who received the HPV vaccine, geometric mean antibody titers were higher among patients with CKD than among patients on dialysis, and both were higher than those in kidney transplant recipients [<a href="#rid46">46</a>]. Across all three groups, patients receiving immunosuppressive medications had a lower antibody response compared with those not receiving these medications.</p><p></p><p class="headingAnchor" id="H1383521412"><span class="h2">COVID-19 vaccine</span><span class="headingEndMark"> — </span>All patients with ESKD should receive COVID-19 vaccination to prevent severe outcomes related to COVID-19. Data on the efficacy of COVID-19 vaccines among patients with ESKD are presented separately. (See  <a class="medical medical_review" href="/z/d/html/130632.html" rel="external">"COVID-19: Issues related to end-stage kidney disease", section on 'Vaccination in patients on dialysis and providers'</a>.) </p><p class="headingAnchor" id="H1249465470"><span class="h2">Respiratory syncytial virus vaccine</span><span class="headingEndMark"> — </span>All patients with ESKD who are 60 years of age or older should receive the respiratory syncytial virus (RSV) vaccine. Additional details regarding available vaccine formulations and administration are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/142052.html" rel="external">"Respiratory syncytial virus infection in adults", section on 'Vaccination'</a>.)</p><p>Older patients with kidney disorders are considered at high risk for severe RSV disease [<a href="#rid47">47</a>]. Although patients with advanced kidney disease were not excluded from RSV vaccine trials, there is a paucity of data on the efficacy of RSV vaccination in patients with ESKD. </p><p class="headingAnchor" id="H943577313"><span class="h2">Rabies vaccine</span><span class="headingEndMark"> — </span>If indicated, dialysis patients should also be vaccinated for rabies. One study demonstrated the effectiveness of the immunological response of well-dialyzed patients on hemodialysis who received intradermal rabies vaccination [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/z/d/html/8328.html" rel="external">"Indications for post-exposure rabies prophylaxis"</a>.)</p><p class="headingAnchor" id="H3092728181"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112932.html" rel="external">"Society guideline links: Dialysis"</a>.)</p><p class="headingAnchor" id="H7203538"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles </strong>– Infections are a leading cause of morbidity and mortality among patients with end-stage kidney disease (ESKD). Although vaccines can help prevent many of the most common infections to which these patients are exposed, patients with ESKD have a reduced response to vaccination. (See <a class="local">'Vaccine efficacy in end-stage kidney disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recommended vaccines </strong>– Patients with ESKD who are not up to date on other routinely recommended vaccines (based on age and other risk factors) should receive any needed vaccines  (<a class="graphic graphic_figure graphicRef82634" href="/z/d/graphic/82634.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef62130" href="/z/d/graphic/62130.html" rel="external">figure 2</a>). If patients with ESKD are traveling, they should undergo evaluation for additional vaccination based on their travel destination and potential exposures. </p><p></p><p class="bulletIndent1"><strong>In addition</strong> to routine vaccines recommended for the general population, patients with ESKD should receive the following vaccines (see <a class="local">'Recommended vaccines'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hepatitis B virus (HBV) vaccine (see <a class="local">'Hepatitis B virus vaccine'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Pneumococcal vaccine (see <a class="local">'Pneumococcal vaccine'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Respiratory syncytial virus (RSV) vaccine (for individuals ≥60 years of age) (see <a class="local">'Respiratory syncytial virus vaccine'</a> above)</p><p></p><p class="bulletIndent1">This approach to vaccination is generally consistent with the Advisory Committee on Immunization Practices (ACIP) in the United States. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of vaccination </strong>– For patients with ESKD who are kidney transplant candidates, any needed vaccines should be administered as early as possible provided that a minimum time interval is maintained between vaccination and subsequent transplantation. Vaccination with live vaccines is generally contraindicated posttransplantation when patients are immunosuppressed. For patients with ESKD who are not transplant candidates, any needed vaccines also should be administered as early as possible. (See <a class="local">'Timing of vaccination'</a> above and  <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">"Immunizations in solid organ transplant candidates and recipients"</a>.)</p><p></p><p class="headingAnchor" id="H445276508"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledges Jean Holley, MD, FACP and Jeffrey Doyon MD, PhD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dalrymple LS, Go AS. Epidemiology of acute infections among patients with chronic kidney disease. Clin J Am Soc Nephrol 2008; 3:1487.</a></li><li><a class="nounderline abstract_t">Murthy N, Wodi AP, McNally VV, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2024. MMWR Morb Mortal Wkly Rep 2024; 73:11.</a></li><li><a class="nounderline abstract_t">Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:e44.</a></li><li><a class="nounderline abstract_t">Syed-Ahmed M, Narayanan M. Immune Dysfunction and Risk of Infection in Chronic Kidney Disease. Adv Chronic Kidney Dis 2019; 26:8.</a></li><li><a class="nounderline abstract_t">Rodby RA, Trenholme GM. Vaccination of the dialysis patient. Semin Dial 1991; 4:102.</a></li><li><a class="nounderline abstract_t">Dinits-Pensy M, Forrest GN, Cross AS, Hise MK. The use of vaccines in adult patients with renal disease. Am J Kidney Dis 2005; 46:997.</a></li><li><a class="nounderline abstract_t">Kausz A, Pahari D. The value of vaccination in chronic kidney disease. Semin Dial 2004; 17:9.</a></li><li><a class="nounderline abstract_t">Eleftheriadis T, Antoniadi G, Liakopoulos V, et al. Disturbances of acquired immunity in hemodialysis patients. Semin Dial 2007; 20:440.</a></li><li><a class="nounderline abstract_t">Litjens NH, Huisman M, van den Dorpel M, Betjes MG. Impaired immune responses and antigen-specific memory CD4+ T cells in hemodialysis patients. J Am Soc Nephrol 2008; 19:1483.</a></li><li><a class="nounderline abstract_t">Agrawal S, Gollapudi P, Elahimehr R, et al. Effects of end-stage renal disease and haemodialysis on dendritic cell subsets and basal and LPS-stimulated cytokine production. Nephrol Dial Transplant 2010; 25:737.</a></li><li><a class="nounderline abstract_t">Favero MS, Alter MJ. The reemergence of hepatitis B virus infection in hemodialysis centers. Semin Dial 1996; 9:373.</a></li><li><a class="nounderline abstract_t">Rangel MC, Coronado VG, Euler GL, Strikas RA. Vaccine recommendations for patients on chronic dialysis. The Advisory Committee on Immunization Practices and the American Academy of Pediatrics. Semin Dial 2000; 13:101.</a></li><li><a class="nounderline abstract_t">Moyer LA, Alter MJ, Favero MS. Hemodialysis-associated hepatitis B: Revised recommendations for serologic screening. Semin Dial 1990; 3:201.</a></li><li><a class="nounderline abstract_t">Stevens CE, Alter HJ, Taylor PE, et al. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med 1984; 311:496.</a></li><li><a class="nounderline abstract_t">Buti M, Viladomiu L, Jardi R, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. Am J Nephrol 1992; 12:144.</a></li><li><a class="nounderline abstract_t">Ahuja TS, Kumar S, Mansoury H, et al. Hepatitis B vaccination in human immunodeficiency virus-infected adults receiving hemodialysis. Kidney Int 2005; 67:1136.</a></li><li><a class="nounderline abstract_t">Mitwalli A. Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling. Nephron 1996; 73:417.</a></li><li><a class="nounderline abstract_t">Jackson S, Lentino J, Kopp J, et al. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults. Vaccine 2018; 36:668.</a></li><li><a class="nounderline abstract_t">Kuan RK, Janssen R, Heyward W, et al. Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine. Vaccine 2013; 31:4024.</a></li><li><a class="nounderline abstract_t">Charest AF, Grand'Maison A, McDougall J, Goldstein MB. Evolution of naturally acquired hepatitis B immunity in the long-term hemodialysis population. Am J Kidney Dis 2003; 42:1193.</a></li><li><a class="nounderline abstract_t">Tsouchnikas I, Dounousi E, Xanthopoulou K, et al. Loss of hepatitis B immunity in hemodialysis patients acquired either naturally or after vaccination. Clin Nephrol 2007; 68:228.</a></li><li><a class="nounderline abstract_t">Tung J, Carlisle E, Smieja M, et al. A randomized clinical trial of immunization with combined hepatitis A and B versus hepatitis B alone for hepatitis B seroprotection in hemodialysis patients. Am J Kidney Dis 2010; 56:713.</a></li><li><a class="nounderline abstract_t">Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2018; 67:1.</a></li><li><a class="nounderline abstract_t">Calisti G, Herman O, Powley M, Haque T. Persistence of hepatitis B surface antigen in blood in a chronic haemodialysis patient following vaccination booster. BMJ Case Rep 2014; 2014.</a></li><li><a class="nounderline abstract_t">Janzen L, Minuk GY, Fast M, Bernstein KN. Vaccine-induced hepatitis B surface antigen positivity in adult hemodialysis patients: incidental and surveillance data. J Am Soc Nephrol 1996; 7:1228.</a></li><li><a class="nounderline abstract_t">Bond TC, Spaulding AC, Krisher J, McClellan W. Mortality of dialysis patients according to influenza and pneumococcal vaccination status. Am J Kidney Dis 2012; 60:959.</a></li><li><a class="nounderline abstract_t">Shen AK, Kelman JA, Warnock R, et al. Beneficiary characteristics and vaccinations in the end-stage renal disease Medicare beneficiary population, an analysis of claims data 2006-2015. Vaccine 2017; 35:7302.</a></li><li><a class="nounderline abstract_t">Vandecasteele SJ, De Bacquer D, Caluwe R, et al. Immunogenicity and safety of the 13-valent Pneumococcal Conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naive and pre-immunized patients under treatment with chronic haemodialysis: a longitudinal quasi-experimental phase IV study. Clin Microbiol Infect 2018; 24:65.</a></li><li><a class="nounderline abstract_t">Fuchshuber A, Kühnemund O, Keuth B, et al. Pneumococcal vaccine in children and young adults with chronic renal disease. Nephrol Dial Transplant 1996; 11:468.</a></li><li><a class="nounderline abstract_t">Ortbals DW, Marks ES, Liebhaber H. Influenza immunization in patients with chronic renal disease. JAMA 1978; 239:2562.</a></li><li><a class="nounderline abstract_t">Jordan MC, Rousseau WE, Tegtmeier GE, et al. Immunogenicity of inactivated influenza virus vaccine in chronic renal failure. Ann Intern Med 1973; 79:790.</a></li><li><a class="nounderline abstract_t">Scharpé J, Peetermans WE, Vanwalleghem J, et al. Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: an open-label trial. Am J Kidney Dis 2009; 54:77.</a></li><li><a class="nounderline abstract_t">Crespo M, Collado S, Mir M, et al. Efficacy of influenza A H1N1/2009 vaccine in hemodialysis and kidney transplant patients. Clin J Am Soc Nephrol 2011; 6:2208.</a></li><li><a class="nounderline abstract_t">Gilbertson DT, Unruh M, McBean AM, et al. Influenza vaccine delivery and effectiveness in end-stage renal disease. Kidney Int 2003; 63:738.</a></li><li><a class="nounderline abstract_t">McGrath LJ, Kshirsagar AV, Cole SR, et al. Influenza vaccine effectiveness in patients on hemodialysis: an analysis of a natural experiment. Arch Intern Med 2012; 172:548.</a></li><li><a class="nounderline abstract_t">Robinson CL, Bernstein H, Poehling K, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2020. MMWR Morb Mortal Wkly Rep 2020; 69:130.</a></li><li><a class="nounderline abstract_t">Manley HJ, Lacson EK Jr, Aweh G, et al. Seroresponse to Inactivated and Recombinant Influenza Vaccines Among Maintenance Hemodialysis Patients. Am J Kidney Dis 2022; 80:309.</a></li><li><a class="nounderline abstract_t">Miskulin DC, Weiner DE, Tighiouart H, et al. High-Dose Seasonal Influenza Vaccine in Patients Undergoing Dialysis. Clin J Am Soc Nephrol 2018; 13:1703.</a></li><li><a class="nounderline abstract_t">Butler AM, Layton JB, Dharnidharka VR, et al. Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccine Among Patients Receiving Maintenance Hemodialysis. Am J Kidney Dis 2020; 75:72.</a></li><li><a class="nounderline abstract_t">Ahn JH, Waller JL, Baer SL, et al. Mortality risk after herpes zoster infection in end-stage renal disease patients. Clin Kidney J 2019; 12:101.</a></li><li><a class="nounderline abstract_t">Tseng HF, Luo Y, Shi J, et al. Effectiveness of Herpes Zoster Vaccine in Patients 60 Years and Older With End-stage Renal Disease. Clin Infect Dis 2016; 62:462.</a></li><li><a class="nounderline abstract_t">Martino FK, Pini S, Scaparrotta G, et al. Recombinant Varicella Zoster vaccine in haemodialysis facilities: adherence and safety. J Nephrol 2023; 36:2155.</a></li><li><a class="nounderline abstract_t">Girndt M, Pietsch M, Köhler H. Tetanus immunization and its association to hepatitis B vaccination in patients with chronic renal failure. Am J Kidney Dis 1995; 26:454.</a></li><li><a class="nounderline abstract_t">Meites E, Szilagyi PG, Chesson HW, et al. Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2019; 68:698.</a></li><li><a class="nounderline abstract_t">Nelson DR, Neu AM, Abraham A, et al. Immunogenicity of Human Papillomavirus Recombinant Vaccine in Children with CKD. Clin J Am Soc Nephrol 2016; 11:776.</a></li><li><a class="nounderline abstract_t">Nailescu C, Nelson RD, Verghese PS, et al. Human Papillomavirus Vaccination in Male and Female Adolescents Before and After Kidney Transplantation: A Pediatric Nephrology Research Consortium Study. Front Pediatr 2020; 8:46.</a></li><li><a class="nounderline abstract_t">Melgar M, Britton A, Roper LE, et al. Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72:793.</a></li><li><a class="nounderline abstract_t">Tanisaro T, Tantawichien T, Tiranathanagul K, et al. Neutralizing antibody response after intradermal rabies vaccination in hemodialysis patients. Vaccine 2010; 28:2385.</a></li></ol></div><div id="topicVersionRevision">Topic 1963 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18650409" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Epidemiology of acute infections among patients with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38206880" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2024.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24311479" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30876622" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Immune Dysfunction and Risk of Infection in Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Vaccination of the dialysis patient</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16310566" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The use of vaccines in adult patients with renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14717802" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The value of vaccination in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17897251" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Disturbances of acquired immunity in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18480314" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Impaired immune responses and antigen-specific memory CD4+ T cells in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19903659" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Effects of end-stage renal disease and haemodialysis on dendritic cell subsets and basal and LPS-stimulated cytokine production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The reemergence of hepatitis B virus infection in hemodialysis centers</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10795113" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Vaccine recommendations for patients on chronic dialysis. The Advisory Committee on Immunization Practices and the American Academy of Pediatrics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hemodialysis-associated hepatitis B: Revised recommendations for serologic screening</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6235453" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1415374" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15698455" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hepatitis B vaccination in human immunodeficiency virus-infected adults receiving hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8832600" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29289383" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23707166" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cost-effectiveness of hepatitis B vaccination using HEPLISAV™in selected adult populations compared to Engerix-B®vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14655191" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Evolution of naturally acquired hepatitis B immunity in the long-term hemodialysis population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17969490" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Loss of hepatitis B immunity in hemodialysis patients acquired either naturally or after vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20630640" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A randomized clinical trial of immunization with combined hepatitis A and B versus hepatitis B alone for hepatitis B seroprotection in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29939980" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24916976" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Persistence of hepatitis B surface antigen in blood in a chronic haemodialysis patient following vaccination booster.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8866417" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Vaccine-induced hepatitis B surface antigen positivity in adult hemodialysis patients: incidental and surveillance data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22694948" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Mortality of dialysis patients according to influenza and pneumococcal vaccination status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29132990" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Beneficiary characteristics and vaccinations in the end-stage renal disease Medicare beneficiary population, an analysis of claims data 2006-2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28559003" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Immunogenicity and safety of the 13-valent Pneumococcal Conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naive and pre-immunized patients under treatment with chronic haemodialysis: a longitudinal quasi-experimental phase IV study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8671817" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pneumococcal vaccine in children and young adults with chronic renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/660788" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Influenza immunization in patients with chronic renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4761907" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Immunogenicity of inactivated influenza virus vaccine in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19339089" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: an open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21852661" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Efficacy of influenza A H1N1/2009 vaccine in hemodialysis and kidney transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12631142" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Influenza vaccine delivery and effectiveness in end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22493462" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Influenza vaccine effectiveness in patients on hemodialysis: an analysis of a natural experiment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32027628" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35288216" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Seroresponse to Inactivated and Recombinant Influenza Vaccines Among Maintenance Hemodialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30352787" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : High-Dose Seasonal Influenza Vaccine in Patients Undergoing Dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31378646" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccine Among Patients Receiving Maintenance Hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30746135" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Mortality risk after herpes zoster infection in end-stage renal disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26671505" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effectiveness of Herpes Zoster Vaccine in Patients 60 Years and Older With End-stage Renal Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37392330" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Recombinant Varicella Zoster vaccine in haemodialysis facilities: adherence and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7645553" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Tetanus immunization and its association to hepatitis B vaccination in patients with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31415491" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27055465" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Immunogenicity of Human Papillomavirus Recombinant Vaccine in Children with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32154194" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Human Papillomavirus Vaccination in Male and Female Adolescents Before and After Kidney Transplantation: A Pediatric Nephrology Research Consortium Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37471262" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20085837" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Neutralizing antibody response after intradermal rabies vaccination in hemodialysis patients.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
